| Title |
Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, August 2018
|
| DOI | 10.2147/ndt.s167129 |
| Pubmed ID | |
| Authors |
Pu Zhi, Yanqiong Wang, Wei Quan, Yanli Su, Hui Zhang |
| Abstract |
Hyperprolactinemia is a common side effect of antipsychotic drugs. Although changes of antipsychotic drugs or reduction of their doses can solve this problem, a modification of the treatment regimen can lead to instability in patients. Herein, we followed up a patient with elevated prolactin caused by paliperidone and found that the prolactin level was decreased after the administration of a combination with a low-dose aripiprazole. In addition, we summarized and analyzed the findings from the case and the literature review conducted. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 15 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 27% |
| Researcher | 2 | 13% |
| Student > Doctoral Student | 1 | 7% |
| Other | 1 | 7% |
| Student > Master | 1 | 7% |
| Other | 3 | 20% |
| Unknown | 3 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 2 | 13% |
| Nursing and Health Professions | 2 | 13% |
| Business, Management and Accounting | 1 | 7% |
| Physics and Astronomy | 1 | 7% |
| Earth and Planetary Sciences | 1 | 7% |
| Other | 3 | 20% |
| Unknown | 5 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2018.
All research outputs
#19,954,338
of 25,385,509 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,192
of 3,131 outputs
Outputs of similar age
#249,802
of 341,886 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#36
of 79 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,131 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,886 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.